Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 19/20 | 0.80 |
| ▸ | FKBP5 | Q13451 | 8/20 | 0.80 |
| ▸ | FKBP4 | Q02790 | 7/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15294276 | 1.00 | FKBP1A (0.80) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL10027163 | 0.98 | FKBP1A (0.78) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL29377078 | 0.96 | FKBP1A (0.85) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL26026938 | 0.96 | FKBP1A (0.85) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL13240345 | 0.96 | FKBP1A (0.85) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL15294286 | 0.94 | FKBP1A (0.79) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL15297184 | 0.94 | FKBP1A (0.79) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL15297156 | 0.94 | FKBP1A (0.79) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL15294282 | 0.94 | FKBP1A (0.79) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL10027139 | 0.94 | FKBP1A (0.79) | FKBP1AFKBP5FKBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261023-A1 | SMALL MOLECULE PRINTING | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120041019-A1 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| WO-2010077317-A2 | PROTEASE INHIBITORS | AMPLYX PHARMACEUTICALS, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041019-A1 | PROTEASE INHIBITORS | SERPINB1, PREP, DNPEP | FKBP1A 1184/4885FKBP5 1835/4885FKBP4 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.